Do-Youn Oh, Yoon-Koo Kang, Kohei Shitara, Li-Tzong Chen, Narikazu Boku, Min-Hee Ryu, Sun Young Rha, Jong Gwang Kim, Jin Young Kim, Sang Cheul Oh, Keun-Wook Lee, Jeeyun Lee, Akihito Kawazoe, Hirokazu Shoji, Kensei Yamaguchi, Sung Yong Oh, Li-Yuan Bai, Ming-Huang Chen, Jen-Shi Chen, Kun-Huei Yeh. "Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: A randomized phase 3 trial (ATTRACTION-6).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.4006